Merck Beats Estimates on Keytruda, Raises Outlook
Merck reported better-than-expected first-quarter results, driven by strong demand for its leading cancer drug Keytruda and several newer therapies. The company continues to show resilience despite growing competition in the pharmaceutical sector. Its performance reflects solid execution across core business segments.
The company also updated its 2026 outlook, narrowing revenue guidance and slightly increasing its profit expectations. Favorable foreign exchange trends and steady product demand supported this improved forecast. Merck now expects consistent growth as it navigates a competitive market environment.
However, Merck reported a net loss for the quarter, largely due to a significant charge tied to its acquisition of Cidara Therapeutics. This one-time expense impacted overall profitability but does not reflect underlying business strength.
Strong Revenue Growth Driven by Keytruda
Merck generated $16.29 billion in revenue, marking a 5% year-over-year increase. The pharmaceutical division remained the primary contributor to this growth, highlighting the company’s strong product portfolio. Demand for innovative treatments continues to drive performance.
Keytruda delivered standout results, generating $8.03 billion in sales and exceeding analyst expectations. Growth was fueled by increased use in both early-stage and advanced cancer treatments. The drug remains a key pillar of Merck’s revenue strategy.
The injectable version of Keytruda also gained traction following its recent approval. This more convenient option is expected to support long-term growth and patient adoption. It also helps Merck prepare for future patent challenges.
Additionally, Winrevair contributed significantly to revenue, reflecting strong uptake in both domestic and international markets. Its rapid growth signals strong future potential for the product.
New Products Support Future Growth Strategy
Winrevair generated $525 million in sales during the quarter, surpassing expectations. The drug’s strong performance highlights its growing acceptance among healthcare providers. Its early success positions it as a key growth driver for Merck.
Merck is actively expanding its pipeline to reduce reliance on older drugs facing patent expiration. Strategic acquisitions and continuous innovation remain central to its long-term plan. The company aims to sustain growth through diversification.
Ongoing investments in research and development are helping Merck strengthen its competitive position. These efforts ensure the company remains relevant in a rapidly evolving pharmaceutical landscape.
This strategy is particularly important as drugs like Januvia, Janumet, and eventually Keytruda approach patent expiry.
Read : Uber Bets Big on Travel, Hotels and AI Voice Bookings
Challenges from Vaccine Sales and Market Pressures
Merck faced headwinds in its vaccine segment, particularly with Gardasil, which saw a 19% decline in sales year over year. Weak demand in China, Japan, and the U.S. contributed to this drop. Market conditions continue to impact vaccine performance.
Despite the decline, Gardasil sales still slightly exceeded analyst expectations. This indicates underlying demand remains stable, even amid short-term challenges. The company continues to monitor global trends closely.
Meanwhile, Merck’s animal health division delivered strong results, with sales rising 13%. Increased demand for livestock and companion animal products supported this growth. This segment remains an important contributor to overall revenue.
Overall, Merck continues to balance strong pharmaceutical growth with challenges in certain segments, maintaining a stable outlook for the future.